Source: Cancer medicine [Cancer Med] 2024 Apr; Vol. 13 (8), pp. e7190.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Mogamulizumab-Associated Autoimmune Diseases: Insights From FAERS Database Analysis.

Authors : Zhang G; Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.; Zhang H

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Autoimmune Diseases*/Autoimmune Diseases*/Autoimmune Diseases*/chemically induced ; Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data

Source: Cancer medicine [Cancer Med] 2024 Dec; Vol. 13 (23), pp. e70478.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.

Authors : Xu Y; Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; School of Pharmacy, Capital Medical University, Beijing, China.

Subjects: Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/Antineoplastic Agents, Immunological*/adverse effects ; Liver Failure*; United States/United States/United States/epidemiology

Source: Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9167-9174. Date of Electronic Publication: 2023 Feb 03.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.

Authors : Liu Y; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Subjects: Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/adverse effects ; B7-H1 Antigen*; Male

Source: Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (6), pp. 6637-6648. Date of Electronic Publication: 2022 Nov 24.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

Authors : Shu Y; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Ding Y

Subjects: Poly(ADP-ribose) Polymerase Inhibitors*/Poly(ADP-ribose) Polymerase Inhibitors*/Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects; Aged ; Humans

Source: Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (3), pp. 3365-3375. Date of Electronic Publication: 2022 Jul 24.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Authors : Wilson BE; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.; University of New South Wales, Kensington, NSW, Australia.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Drug Approval/Drug Approval/Drug Approval/*statistics & numerical data ; Neoplasm Recurrence, Local/Neoplasm Recurrence, Local/Neoplasm Recurrence, Local/*epidemiology

Source: Cancer medicine [Cancer Med] 2021 Aug; Vol. 10 (16), pp. 5405-5414. Date of Electronic Publication: 2021 Jul 28.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Authors : Di Maria Jiang; Kelvin K. W. Chan; Raymond W. Jang

Subjects: antineoplastic agents; clinical benefit; drug costs

Source: Cancer Medicine, Vol 8, Iss 4, Pp 1584-1593 (2019)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.

Authors : Yagi K; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.; Mitstui M

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*adverse effects ; Antihypertensive Agents/Antihypertensive Agents/Antihypertensive Agents/*therapeutic use ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*adverse effects

Source: Cancer medicine [Cancer Med] 2021 Jan; Vol. 10 (1), pp. 164-172. Date of Electronic Publication: 2020 Nov 24.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.

Authors : Jiang DM; Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.; Chan KKW

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/economics ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

Source: Cancer medicine [Cancer Med] 2019 Apr; Vol. 8 (4), pp. 1584-1593. Date of Electronic Publication: 2019 Mar 07.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.

Authors : Chen G; Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.; Qin Y

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*adverse effects ; Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/*adverse effects ; Kidney Diseases/Kidney Diseases/Kidney Diseases/*chemically induced

Source: Cancer medicine [Cancer Med] 2020 Sep; Vol. 9 (18), pp. 6576-6585. Date of Electronic Publication: 2020 Jul 27.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).

Mogamulizumab-Associated Autoimmune Diseases: Insights From FAERS Database Analysis.

Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.

Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.

Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.

اتصل بنا

اتبع